We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$1.24M
Cap. Flow
+$25.3M
Cap. Flow %
21.92%
Top 10 Hldgs %
67.87%
Holding
48
New
20
Increased
9
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$9.08M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$6.43M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$5.79M
4
TERN
Terns Pharmaceuticals
TERN
+$4.55M
5
URGN icon
UroGen Pharma
URGN
+$3.61M

Top Sells

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$6.2M
2
CAPR icon
Capricor Therapeutics
CAPR
+$4.94M
3
CYTK icon
Cytokinetics
CYTK
+$4.49M
4
ETNB
89bio
ETNB
+$3.81M
5
NKTX icon
Nkarta
NKTX
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
1
Oric Pharmaceuticals
ORIC
$1.11B
$12.8M 11.05%
1,580,745
+631,223
+66% +$5.79M
TERN
2
DELISTED
Terns Pharmaceuticals
TERN
$11.2M 9.69%
2,020,562
+672,016
+50% +$4.55M
ZLAB icon
3
Zai Lab
ZLAB
$2.28B
$10.6M 9.15%
403,630
-223,302
-36% -$6.2M
NVCR icon
4
NovoCure
NVCR
$1.84B
$8.55M 7.41%
286,970
-105,741
-27% -$2.24M
BBIO icon
5
BridgeBio Pharma
BBIO
$15.9B
$7.19M 6.23%
262,141
+35,457
+16% +$916K
COGT icon
6
Cogent Biosciences
COGT
$6.68B
$7.1M 6.15%
+910,865
New +$9.08M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
$6.09M 5.27%
129,389
-86,409
-40% -$4.49M
GPCR icon
8
Structure Therapeutics
GPCR
$3.45B
$5.88M 5.09%
216,811
-10,236
-5% -$363K
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.47B
$5.84M 5.05%
+227,102
New +$6.43M
URGN icon
10
UroGen Pharma
URGN
$1.96B
$3.21M 2.78%
+301,206
New +$3.61M
SMMT icon
11
Summit Therapeutics
SMMT
$10.7B
$2.94M 2.54%
+164,564
New +$3.19M
TIL icon
12
Instil Bio
TIL
$50.3M
$2.83M 2.45%
148,017
+40,472
+38% +$1.23M
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.06B
$2.66M 2.3%
+68,892
New +$3M
INSM icon
14
Insmed
INSM
$23.5B
$2.48M 2.15%
+35,966
New +$2.59M
FATE icon
15
Fate Therapeutics
FATE
$324M
$2.28M 1.97%
1,379,556
-87,378
-6% -$220K
LEGN icon
16
Legend Biotech
LEGN
$4.31B
$2.26M 1.96%
69,594
+9,079
+15% +$376K
TARA icon
17
Protara Therapeutics
TARA
$230M
$1.9M 1.65%
+360,000
New +$1.16M
CABA icon
18
Cabaletta Bio
CABA
$461M
$1.87M 1.62%
822,293
+690,498
+524% +$2.42M
DYN icon
19
Dyne Therapeutics
DYN
$3.92B
$1.72M 1.49%
+73,150
New +$2.16M
ORIC icon
20
CALL
Oric Pharmaceuticals
ORIC
$1.11B
$1.61M 1.4%
+200,000
New +$1.84M
SVRA icon
21
Savara
SVRA
$1.13B
$1.56M 1.35%
508,338
+308,338
+154% +$1.08M
TNGX icon
22
Tango Therapeutics
TNGX
$4.65B
$1.47M 1.27%
474,955
-124,093
-21% -$576K
KURA icon
23
Kura Oncology
KURA
$964M
$1.38M 1.19%
+157,959
New +$2.27M
INCY icon
24
Incyte
INCY
$23.4B
$1.24M 1.08%
+18,009
New +$1.28M
ONC
25
BeOne Medicines Ltd
ONC
$32.4B
$1.18M 1.02%
+6,365
New +$1.3M
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Superstring Capital Management held 48 positions worth $115M, up 1.1% from $114M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Superstring Capital Management deployed $25.3M of net new capital in Q4 2024, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Cogent Biosciences: 910,865 shares worth $7.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Zai Lab, an estimated $6.2M trimmed.

  • Superstring Capital Management's largest Q4 2024 buy was Cogent Biosciences: 910,865 shares worth $7.1M.
  • Superstring Capital Management added most to Oric Pharmaceuticals in Q4 2024, an estimated $5.79M increase.
  • Superstring Capital Management's biggest Q4 2024 reduction was Zai Lab, cutting an estimated $6.2M.
  • Superstring Capital Management fully exited Nkarta in Q4 2024, selling an estimated $3.35M.
  • Superstring Capital Management's ten largest holdings make up 68% of its $115M portfolio in Q4 2024.
  • Superstring Capital Management opened 20 new positions and closed 9 in Q4 2024.
  • Superstring Capital Management's portfolio value rose 1.1% quarter-over-quarter to $115M.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.